Top Pharmaceutical Companies in Los Angeles, CA (88)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.
Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.
Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.
Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group
At Solventum, we enable better, smarter, safer healthcare to improve lives. We never stop solving for you
Solventum's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is a leader or co‑leader in core niches such as negative‑pressure wound therapy and hospital coding/CDI software, with widely deployed platforms and recognized standings. Brand strength and installed bases across MedSurg, Dental, and HIS reinforce competitive positioning.
Resilient & Sustainable Growth: Recent quarters show positive organic sales growth, and guidance points to continued low‑single‑digit expansion. Feedback suggests momentum is supported across key segments, aligning with a steady, incremental trajectory.
Future-Ready Strategy: Management outlines a multi‑year plan centered on portfolio focus, R&D‑led innovation, and selective M&A to accelerate growth. Actions such as SKU rationalization, product launches, and targeted partnerships indicate preparation for longer‑term expansion.
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
.png)
Sleuth is a startup that delivers done-for-you competitive intelligence insights and reports to biopharma companies and investors. We use AI agents and a proprietary database of over 100M data points and documents to power bespoke analyses for executives and a range of business-focused teams across the industry. Among our current customers are some of the largest pharma companies in the...
U.S. Dermatology Partners is one of the largest physician-owned dermatology practices in the United States, providing premier medical, surgical, and cosmetic skin care to over two million patients annually. With more than 130 locations across nine states, the organization focuses on patient-first care, combining the personalized experience of private practice with a coordinated network of specialized physicians and national thought...
RelaDyne, headquartered in Cincinnati, OH, combines many years of expertise with our valued associates to serve more than 10,000 clients in the automotive, commercial and industrial industries. We strive to deliver valuable, dependable service and effective solutions as a trusted partner to our customers. Our core business, focused on lubrication excellence, is accomplished through offering unmatched products and services in which...
RelaDyne LLC's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is widely cited as the nation’s largest lubricant distributor with leadership across lubricants, fuels/DEF, and industrial reliability services. Its standing in a fragmented market and industry recognition signal durable competitive advantages with large industrial and commercial clients.
Market Expansion: Feedback suggests sustained geographic growth to 190+ locations driven by an active acquisition program, including multiple deals in 2025–2026 that extend coverage across the West Coast, Midwest, and Northeast. The relocation of headquarters to Houston is framed as supporting additional scale, job growth, and proximity to key partners.
Investor Backing & Capital Strength: Private‑equity ownership and portfolio materials describing multibillion‑dollar scale indicate resources to continue organic expansion and M&A. This backing is repeatedly linked to momentum for further acquisitions and network densification.
ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. ACELYRIN is embedding a corporate culture of Courageous Caring™—placing patients first and embracing the concept that all of us are better than any...
CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically...
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is a leading nonprofit research organization focused on biomedical innovation, translating discovery into health impact through research, education, and community outreach.
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer and other urologic diseases.
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the...
Insulet's Top Stability & Growth Strengths
Strong Revenue Growth: Company reported accelerating revenue growth across 2024–2025 and guided continued double‑digit expansion for 2026. Quarterly updates highlighted broad‑based momentum in both U.S. and international markets.
Strong Market Position & Advantage: Omnipod leads the tubeless/patch‑pump segment and ranked No. 1 in new customer starts in the U.S. and Europe in 2024–2025, reinforcing competitive momentum. First‑to‑market AID clearance for adults with type 2 diabetes and broad CGM integrations bolster positioning.
Market Expansion: International rollouts and expansion into type 2 diabetes materially increased the addressable market and active user base. Added manufacturing capacity in Malaysia supports global demand and cost scaling.
Obagi Cosmeceuticals is a specialty pharmaceutical company that develops, markets and sells, and is the leading provider of proprietary topical aesthetic and therapeutic clinically-proven skin care systems in the physician-dispensed market. The systems are designed to prevent and improve the most common and visible skin disorders. The foundation of the company began in 1988 with the creation of the Obagi...
Anton Paar develops, produces, distributes and provides support for analytical instruments used in research, development and quality control worldwide. Ever since Mr. Anton Paar founded his one-man workshop in 1922, the Austrian based company has continuously found new ways to merge high-precision engineering with scientific curiosity. The company currently has more than 3500 employees and is active in over 170...
Siragen Pharmaceuticals is an innovative biotechnology company.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. We are powered...
Novo Nordisk's Top Stability & Growth Strengths
Strong Market Position & Advantage: Novo Nordisk is characterized as a global leader in GLP‑1–based diabetes and obesity care, anchored by clinically differentiated products like Wegovy and a broad GLP‑1 portfolio. While shares fluctuate by geography, disclosures and independent analyses continue to frame the company as a category leader.
Innovation-Driven Growth: Cardiovascular outcomes data supporting Wegovy’s label expansion and the first approved oral GLP‑1 for chronic weight management, together with late‑stage assets (e.g., amycretin/zenagamtide, CagriSema), strengthen adoption arguments and extend the franchise.
Market Expansion: U.S. launch momentum for the Wegovy pill, EU approval, and planned international rollouts in 2026 are broadening access and the addressable market. Significant capacity additions, including acquired fill‑finish sites and new investments, are intended to support higher volumes across regions.
Irvine Clinical Research is the largest independent clinical research site network on the US West Coast. Founded in 1978, the company specializes in conducting clinical trials for neurology, psychiatry, and obesity medicine. They provide clinical research opportunities and solutions to participants and sponsors, offering study-related medical care and medications at no cost to qualified participants, with a strong focus on...
Procter & Gamble Company is an American multi-national consumer goods corporation. P&G was founded over 180 years ago as a soap and candle company. Today, we’re the world’s largest consumer goods company and home to iconic, trusted brands, including Always®, Charmin®, Braun®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Oral B®, Pantene®, Pampers®, Tide®, and Vicks®. The design, development, growth and...
Procter & Gamble's Top Stability & Growth Strengths
Strong Market Position & Advantage: P&G is consistently characterized as the clear industry leader with dominant positions across core categories, anchored by flagship brands like Tide, Pampers, Gillette, Crest, and Oral‑B. Multiple sources in the provided materials frame it as leading peers across home care, baby/feminine, grooming, and oral care.
Innovation-Driven Growth: The company is repeatedly recognized for leadership in product innovation and is advancing new formats and data‑driven operations to sustain momentum. References cite top‑ranked innovation in household products for multiple consecutive years and highlight launches such as new detergent formats.
Resilient & Sustainable Growth: Recent updates indicate a return to positive unit volumes with modest organic sales and EPS increases, alongside reaffirmed low single‑digit growth guidance. Dividend increases and ongoing cash returns are emphasized as continuing, underscoring a steady, durable profile.
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best. The neuroscience market is on a growth trajectory. We see...
Lundbeck's Top Stability & Growth Strengths
Strong Revenue Growth: Feedback suggests total revenue increased at constant exchange rates across 2025 and into H1 2026, with double-digit gains in the U.S. and Europe supporting momentum.
Profitability: Earnings are considered to have scaled alongside revenue, with adjusted EBITDA rising materially, indicating improved profit leverage.
Product Line Growth: Strategic brands such as Vyepti and Rexulti are often cited as the primary engines of expansion, showing strong double-digit growth and contributing the majority of total revenue.
